Personal information

No personal information available

Activities

Education and qualifications (2)

Yale University School of Medicine: New Haven, CT, US

2014-08-01 to present | MD PhD (Immunology)
Education
Source: Self-asserted source
Daniel Kim

Harvard College: Cambridge, MA, US

2009-08-01 to 2014-05-01 | AB (Chemical and Physical Biology)
Education
Source: Self-asserted source
Daniel Kim

Funding (1)

Exploring the Innate Sensors Underlying Cancer Immunosurveillance

2019-01-01 to 2021-12-31 | Grant
National Cancer Institute (Rockville, US)
GRANT_NUMBER: F30CA236466
Source: Self-asserted source
Daniel Kim via DimensionsWizard

Works (10)

UVB-mediated DNA damage induces matrix metalloproteinases to promote photoaging in an AhR- and SP1-dependent manner

JCI Insight
2022-05-09 | Journal article
Contributors: Daniel J. Kim; Akiko Iwasaki; Anna L. Chien; Sewon Kang
Source: check_circle
Crossref

RUNX binding sites are enriched in herpesvirus genomes and RUNX1 overexpression leads to HSV-1 suppression.

Journal of virology
2020-09-02 | Journal article
Source: Self-asserted source
Daniel Kim

Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2.

The New England journal of medicine
2020-08-28 | Journal article
Source: Self-asserted source
Daniel Kim

Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets.

Nature microbiology
2020-07-10 | Journal article
Source: Self-asserted source
Daniel Kim

Vitamin B12 and folic acid alleviate symptoms of nutritional deficiency by antagonizing aryl hydrocarbon receptor.

Proceedings of the National Academy of Sciences of the United States of America
2020-06-22 | Journal article
Source: Self-asserted source
Daniel Kim
grade
Preferred source (of 2)‎

Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies.

Nature communications
2019-11-14 | Journal article
Source: Self-asserted source
Daniel Kim

Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses.

The Journal of experimental medicine
2019-10-10 | Journal article
Source: Self-asserted source
Daniel Kim

YTHDF1 Control of Dendritic Cell Cross-Priming as a Possible Target of Cancer Immunotherapy.

Biochemistry
2019-04-03 | Journal article
Source: Self-asserted source
Daniel Kim

Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014-02-03 | Journal article
Source: Self-asserted source
Daniel Kim

Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.

Cancer cell
2013-01-03 | Journal article
Source: Self-asserted source
Daniel Kim